Literature DB >> 22531441

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Shan Chung1, Valerie Quarmby, Xiaoying Gao, Yong Ying, Linda Lin, Chae Reed, Chris Fong, Wendy Lau, Zhihua J Qiu, Amy Shen, Martin Vanderlaan, An Song.   

Abstract

The presence or absence of core fucose in the Fc region N-linked glycans of antibodies affects their binding affinity toward FcγRIIIa as well as their antibody-dependent cell-mediated cytotoxicity (ADCC) activity. However, the quantitative nature of this structure-function relationship remains unclear. In this study, the in vitro biological activity of an afucosylated anti-CD20 antibody was fully characterized. Further, the effect of fucose reduction on Fc effector functions was quantitatively evaluated using the afucosylated antibody, its "regular" fucosylated counterpart and a series of mixtures containing varying proportions of "regular" and afucosylated materials. Compared with the "regular" fucosylated antibody, the afucosylated antibody demonstrated similar binding interactions with the target antigen (CD20), C1q and FcγRIa, moderate increases in binding to FcγRIIa and IIb, and substantially increased binding to FcγRIIIa. The afucosylated antibodies also showed comparable complement-dependent cytotoxicity activity but markedly increased ADCC activity. Based on EC 50 values derived from dose-response curves, our results indicate that the amount of afucosylated glycan in antibody samples correlate with both FcγRIIIa binding activity and ADCC activity in a linear fashion. Furthermore, the extent of ADCC enhancement due to fucose depletion was not affected by the FcγRIIIa genotype of the effector cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531441      PMCID: PMC3355491          DOI: 10.4161/mabs.19941

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  49 in total

1.  The structure of a human type III Fcgamma receptor in complex with Fc.

Authors:  S Radaev; S Motyka; W H Fridman; C Sautes-Fridman; P D Sun
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

2.  Molecular basis for immune complex recognition: a comparison of Fc-receptor structures.

Authors:  P Sondermann; J Kaiser; U Jacob
Journal:  J Mol Biol       Date:  2001-06-08       Impact factor: 5.469

3.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

4.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

5.  Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.

Authors:  Alfred Schnueriger; Roger Grau; Peter Sondermann; Thomas Schreitmueller; Stefan Marti; Marcel Zocher
Journal:  Mol Immunol       Date:  2011-05-14       Impact factor: 4.407

Review 6.  Interaction sites on human IgG-Fc for FcgammaR: current models.

Authors:  Roy Jefferis; John Lund
Journal:  Immunol Lett       Date:  2002-06-03       Impact factor: 3.685

7.  Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors.

Authors:  S Radaev; P D Sun
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

8.  Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding.

Authors:  Y Mimura; P Sondermann; R Ghirlando; J Lund; S P Young; M Goodall; R Jefferis
Journal:  J Biol Chem       Date:  2001-09-20       Impact factor: 5.157

9.  A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry.

Authors:  Julian A Saba; Jeremy P Kunkel; David C H Jan; Werner E Ens; Kenneth G Standing; Michael Butler; James C Jamieson; Hélène Perreault
Journal:  Anal Biochem       Date:  2002-06-01       Impact factor: 3.365

10.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics.

Authors:  T S Raju; J B Briggs; S M Borge; A J Jones
Journal:  Glycobiology       Date:  2000-05       Impact factor: 4.313

View more
  46 in total

Review 1.  Biosimilarity Versus Manufacturing Change: Two Distinct Concepts.

Authors:  Paul Declerck; Mourad Farouk-Rezk; Pauline M Rudd
Journal:  Pharm Res       Date:  2015-09-17       Impact factor: 4.200

2.  The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.

Authors:  Lowell J Brady; Jyoti Velayudhan; Devi B Visone; Ken C Daugherty; Jeff L Bartron; Michael Coon; Cabot Cornwall; Peter J Hinckley; Lisa Connell-Crowley
Journal:  MAbs       Date:  2015       Impact factor: 5.857

3.  Glycoengineering of Mammalian Expression Systems on a Cellular Level.

Authors:  Kelley M Heffner; Qiong Wang; Deniz Baycin Hizal; Özge Can; Michael J Betenbaugh
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

4.  A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Yuling Wu; Jia J Li; Hyun Jun Kim; Xu Liu; Weiyi Liu; Ahmad Akhgar; Michael A Bowen; Susan Spitz; Xu-Rong Jiang; Lorin K Roskos; Wendy I White
Journal:  AAPS J       Date:  2015-07-24       Impact factor: 4.009

5.  Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.

Authors:  Yun Yang; Qingcheng Guo; Mao Xia; Yantao Li; Xiaoyun Peng; Tao Liu; Xin Tong; Jin Xu; Huaizu Guo; Weizhu Qian; Sheng Hou; Jianxin Dai; Hao Wang; Rong Liu; Yajun Guo
Journal:  MAbs       Date:  2015       Impact factor: 5.857

6.  Chemical Structure and Composition of Major Glycans Covalently Linked to Therapeutic Monoclonal Antibodies by Middle-Down Nuclear Magnetic Resonance.

Authors:  Jiangnan Peng; Sharadrao M Patil; David A Keire; Kang Chen
Journal:  Anal Chem       Date:  2018-08-27       Impact factor: 6.986

7.  Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.

Authors:  Qian Gong; Meredith Hazen; Brett Marshall; Susan R Crowell; Qinglin Ou; Athena W Wong; Wilson Phung; Jean-Michel Vernes; Y Gloria Meng; Max Tejada; Dana Andersen; Robert F Kelley
Journal:  MAbs       Date:  2016-05-24       Impact factor: 5.857

8.  Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates.

Authors:  Hong Wang; Linping Wu; Can Wang; Jin Xu; Hongrui Yin; Huaizu Guo; Luxia Zheng; Hong Shao; Gang Chen
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-12

Review 9.  Overview of Humira® Biosimilars: Current European Landscape and Future Implications.

Authors:  Jill Coghlan; Hongliang He; Anna S Schwendeman
Journal:  J Pharm Sci       Date:  2021-02-05       Impact factor: 3.534

Review 10.  Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain.

Authors:  William M Pardridge
Journal:  Front Med Technol       Date:  2020-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.